Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Short DNA strands in the genome may be key to understanding human cognition and diseases

22.11.2012
Previously discarded, human-specific 'junk' DNA represents untapped resource in the study of diseases like Alzheimer's and autism

Short snippets of DNA found in human brain tissue provide new insight into human cognitive function and risk for developing certain neurological diseases, according to researchers from the Departments of Psychiatry and Neuroscience at Mount Sinai School of Medicine. The findings are published in the November 20th issue of PLoS Biology.

There are nearly 40 million positions in the human genome with DNA sequences that are different than those in non-human primates, making the task of learning which are important and which are inconsequential a challenge for scientists. Rather than comparing these sequences strand by strand, Schahram Akbarian, MD, PhD, Professor of Psychiatry and Neuroscience at Mount Sinai School of Medicine, wanted to identify the crucial set of differences between the two genomes by looking more broadly at the chromatin, the structure that packages the DNA and controls how it is expressed.

They found hundreds of regions throughout the human genome which showed a markedly different chromatin structure in neurons in the prefrontal cortex, a brain region that controls complex emotional and cognitive behavior, compared to non-human primates. The findings of the study provide important insights for diseases that are unique to humans such as Alzheimer's disease and autism.

"While mapping the human genome has taught us a great deal about human biology, the emerging field of epigenomics may help us identify previously overlooked or discarded sequences that are key to understanding disease," said Dr. Akbarian. "We identified hundreds of loci that represent untapped areas of study that may have therapeutic potential."

Dr. Akbarian and his research team isolated small snippets of chromatin fibers from the prefrontal cortex. Next, they analyzed these snippets to determine what genetic signals they were expressing. Many of the sequences with human-specific epigenetic characteristics were, until recently, considered to be "junk DNA" with no particular function.

Now, they present new leads on how the human brain has evolved, and a starting point for studying neurological diseases. For example, the sequence of DPP10—a gene critically important for normal human brain development—not only showed distinct human-specific chromatin structures different from other primate brains such as the chimpanzee or the macaque, but the underlying DNA sequence showed some interesting differences from two extinct primates—the Neanderthal and Denisovan, most closely related to our own species and also referred to as 'archaic hominins'.

"Many neurological disorders are unique to human and are very hard as a clinical syndrome to study in animals, such as Alzheimer's disease, autism, and depression," said Dr. Akbarian. "By studying epigenetics we can learn more about those unique pieces of the human genome."

The research team also discovered that several of these chromatin regions appear to physically interact with each other inside the cell nucleus, despite being separated by hundreds of thousands of DNA strands on the genome. This phenomenon of "chromatin looping" appears to control the expression of neighboring genes, including several with a critical role for human brain development.

"There is growing consensus among genome researchers that much of what was previously considered as 'junk sequences' in our genomes indeed could play some sort of regulatory role," said Dr. Akbarian.

This study was supported by grants from the National Institutes of Health. Dr. Akbarian plans to do more epigenetic studies in other areas of the brain to see if there are additional chromatin regions that are unique to humans. They also plan to study the epigenomes of other mammals with highly evolved social behaviors such as elephants.

Dr. Akbarian joined Mount Sinai in July 2012. He is internationally known for his cutting-edge research on the epigenetic mechanisms of psychiatric disorders. He is a widely recognized expert in advanced chromatin tools—many of which were developed in his laboratory—in conjunction with mouse mutagenesis and behavioral models of mental illness to bridge molecular, cellular, and behavioral investigations. He is also a renowned authority on the epigenetic analysis of human brain tissue examined postmortem.

Prior to joining Mount Sinai, Dr. Akbarian was Director of the Brudnick Neuropsychiatric Research Institute. He received his medical and doctorate degrees from the Freie Universitaet Berlin. Dr. Akbarian completed his postdoctoral training in neuroscience at the University of California at Irvine and the Whitehead Institute, and his residency in psychiatry at Massachusetts General Hospital.


About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by US News and World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2011, US News and World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and US News and World Report and whose hospital is on the US News and World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

Mount Sinai Press Office | EurekAlert!
Further information:
http://www.mssm.edu
http://www.mountsinai.org/

More articles from Life Sciences:

nachricht Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover

nachricht First transcription atlas of all wheat genes expands prospects for research and cultivation
17.08.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>